Cantor Fitzgerald Downgrades Crinetics Pharmaceuticals to Neutral

Benzinga Newsdesk www.benzinga.com Negative 84.2%

Neg 84.2% Neu 0% Pos 0%

Cantor Fitzgerald analyst Josh Schimmer downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Overweight to Neutral.

Comments

No comments yet. Be the first!